Incyte Corporation Stock News

Incyte Corporation (NASDAQ:INCY ) Q1 2022 Earnings Conference Call May 3, 2022 8:00 AM ET Company Participants Christine Chiou – Head-Investor Relations Hervé Hoppenot – Chairman, President and C

Incyte (INCY) delivered earnings and revenue surprises of -3.51% and 4%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Let's look at the five biotech/pharma companies, slated to release quarterly results on May 3.

Which biotech stocks do you have on your May 2022 watchlist?

These are the best Nasdaq stocks to invest in now. INCY, ROKU and FTXL can make great investments in the rest of the year.

Jakafi (ruxolitinib) sales were up 15% y/y and the label is expanding. Olumiant is ramping up royalties.

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, May 3, 2022.

These two companies offer products that are always in demand, regardless of economic conditions.

Incyte: All Atention On Opzelura

The recent pipeline setbacks will weigh on Incyte's (INCY) growth trajectory and jeopardize its plans to diversify its revenue base.

Incyte' s (INCY) sNDA seeking label expansion of ruxolitinib cream gets extended by three months by the FDA for reviewing additional information.

The U.S. Food and Drug Administration extended the review period by three months for Incyte''s (INCY) application seeking extended approval of ruxolitinib cream (Opzelura) to…

The FDA has extended the review period for Incyte Corporation''s (NASDAQ: INCY ) supplemental application for ruxolitinib cream (Opzelura) for vitiligo. The Prescription Drug User Fee Act (PDUFA) action date has been extended by three months to July 18 from April 18 . The FDA … Full story available on Benzinga.com

Although US stock futures traded higher this morning on Friday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that

Most investors are likely familiar with the adage, "actions speak louder than words." That saying certainly applies to the executives and other corporate insiders buying and selling shares of their own company''s stock. It''s part of an executive''s job to paint a rosy public picture of the future of a company, but a CEO''s bullish words may not be an accurate reflection of how he or she truly feels about a stock. However, if company insiders are backing up positive words with insider buying, it can be a confirming indication that management is truly bullish enough about the future to put their own skin in the game. Here are seven stocks that Bank of America analysts recommend that have seen insider ownership increase in the last year. Incyte Corporation (NASDAQ: INCY ) Incyte develops and commercializes oncology therapies. Analyst Tazeen Ahmad says Jakafi, a medication used to treat certain bone marrow disorders, and additional revenue streams provide a floor under Incyte''s valuation, and the company''s late-stage dermatology program could be a near-term growth catalyst.